1Ottm ann OG,D ruker B J,Saw yers CL,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chro- mosome positive acute lymphoid leukemias[J]. Blood ,2002,100: 1965-1971.
2Wassm ann B,Pfeifer H,Stadler M,et al. Early molecular re- sponse to posttran splantation imatinib determines outcome inMRD +Philadelhia-positive acute lymphoblastic leukemia (Ph + ALL)[J]. Blood,2005,106:458-463.
3Fei F,Stoddart S,Groffen J,et al. Activity of the Aurora kinase inhibitor VX-680 against Bcr/Abl-positive acute lymphoblastic leukemias[J]. Mol Cancer Ther,2010,9 : 1318-1327.
4Bernardin F,Yang Y,Cleaves R,et al. TEL-AML1 ,expressed from t (12;21) in human acute lymphocytic leukemia,induces acute leukemia in mice[J]. Cancer Res,2002,62:3904-3908.
5Gilliland DG,Jordan CT,Felix CA. The molecular basis of leukemi- a[J]. Hematology Am Soc Hematol Educ Program,2004: 80-97.
6Baruchel A,Cayuela JM,MacIntyre E,et al. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by sin- gle-strand conformation polymorphism studies and highly resolu- tive PCR derived methods:implication for a general strategy of minimal sidual disease detection [J]. Br J Haematol, 1995,90: 85-93.
8Sawinska M,Ladon D. Mechanism,detection and clinical signifi- cance of the reciprocal translocation t (12;21)(p12;q22) in the children suffering from acute lymphoblastic leukaemia [J]. Leuk Res, 2004,28 : 35-42.
9Frost BM, Forestier E, Gustafsson G, et al. Translocation t (12; 21) isrelated to in vitro cellular drug sensitivity to doxorub icin and e- toposidein childhood acute lymphob last ic leuk em ia [J]. Blood, 2004,104: 2452-2457.
10Ram akers-vanWoerd enNL,P ietersR, Loon enAH,et al. TEL/ AMLlgene fusion is related to in vitro drug sensitivity for L - asparaginase in childhood acute lymphob last ic leukemia [J]. Blood,2000,96:1094- 1099.
2Pallisgaard N, Hokland P, Riishoj D C, et al. Multiplex reverse transcription polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia [J]. Blood, 1998,92(2) :574-588.
3Collins-Underwood J R, Mullighan C G. Genomic profiling of high-risk acute lymphoblastic leukemia [J].Leukemia, 2010,24(10) : 1676-1685.
4Gao Y J, Zhu X H, Yang Y, et al. Prevalence of ETV6- RUNX1 fusion gene in children with acute lymphoblastie leukemia in China[J].Cancer Genet Cytogenet, 2007,178 (1):57-60.
5Vrooman L M, Silverman L B. Childhood acute lymphoblastic leukemia: update on prognostic factors [J]. Curr Opin Pediatr, 2009,21(1):1-8.
6Pieters R, Sehrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastie leukaemia (Interfant-99) : an ohservational study and a multi-centre randomised trial [ J ]. Lancet, 2007,370 (9583) : 240-250.
7Pui C H, Gaynon P S, Boyett J M, et al. Outcome of treatment in childhood acute lymphoblastic leukemia with rearrangements of the 11q23 chromosomal region [J]. Lancet, 2002.359 (9321) : 1909-1915.
8Marcucci G, Claudia C D, Ruppert A S, et al. Overexpression of the ETS-Related genes, ERG, predicts a outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B Study [J]. J Clin Oncol, 2005,23 (36) : 9234-9242.
9Kanazawa T, Ogawa C, Taketani T, et al. TLS/FUS-ERG fusion gene in acute lymphoblastic leukemia with t (16;21) (p11;q22)and monitoring of minimal residual disease [J]. Leuk Lymphoma, 2005,46(12) : 1833-1835.
1Rowe JM.Getting to the root of(it)ALL[J].Blood,2010,115(18):3649-3650.
2Rowe JM,Buck G,Burnett AK,et al.Induction therapy for adults with acute lymphoblastic leukemia:results of more than 1500patients from the international ALL trial:MRC UKALLⅫ/ECOG E2993[J].Blood,2005,106(12):3760-3767.
3Moorman AV,Chilton L,Wilkinson J,et al.A population-based cytogeneticstudy of adults with acute lymphoblastic leukemia[J].Blood,2010,115(2):206-214.
4Ottmann OG,Pfeifer H.Management of Philadelphia chromosomepositive acute lymphoblastic leukemia(Ph+ALL)[J].Hematology Am Soc of Hematol Educ Program,2009:371-381.
5Fielding AK.Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia[J].Haematologica,2010,95(1):8-12.
6Brüggemann M,Raff T,Flohr T,et al.Clinical signifycance of minimal residual disease quantification in adult patients with standard risk acute lymphoblastic leukemia[J].Blood,2006,107(3):1116-1123.
7Piccaluga PP,Paolini S,Martinelli G.Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia[J].Cancer,2007,110(6):1178-1186.
9Lichty BD, Keating A, Callum J, et al. Expression of p210 and plg0 BCR-ABL due to alternative splicing in chronic myclogenous leukaemia [ J ]. Br J Haematol, 1998,103 (3) :71 1-715.
10Vancken JW, Kaartinen V ,Pattengale PK ,et al. BCR/ABL 17210 and P190 cause distinct leukemia in transgenic mice [ J ]. Blood, 1995,86(12) :4603-4611.
